Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered…
By M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana‐Hulin, S. Chan, D. Grimes, A. Antón, A. Lluch and 7 more. Journal of Clinical Oncology, 2005
1,589 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/946ff84580da061e00e3c01c7854132bb530182e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. (2006, background): “Herceptin trials were very successful, showing a 23% response rate in a targeted population (48).”
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011, positive): “Treatment with the anti-HER2 humanized monoclonal antibody trastuzumab in addition to chemotherapy, as compared with chemotherapy alone, significantly improves progression-free and overall survival among patients with HER2-positive metastatic breast cancer.(3,4) Trastuzumab binds to subdomain IV of ”
- Risk Factors and Preventions of Breast Cancer (2017, methodology): “A randomized phase II trial executed by Marty also showed that trastuzumab plus docetaxel was more efficacious than docetaxel alone in treating HER2-positive MBC, with the ORR of 50% versus 32% [122].”
- Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, background): “However, the incidence of ocetaxel-induced HF was higher (8%) in another breast ancer trial (16).”
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, background): “and improves survival in the first-line setting when combined with chemotherapy in patients with advanced diseas”